Selected research
Industry Research
Preventive Asthma Drug Industry Research Report 2026
Market perspective
The global Preventive Asthma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Preventive Asthma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Preventive Asthma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Preventive Asthma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Preventive Asthma Drug include Callisto Pharmaceuticals, Molecular Insight Pharmaceuticals, Xiaflex, Roche and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Preventive Asthma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Preventive Asthma Drug Market by Company
Callisto Pharmaceuticals
Molecular Insight Pharmaceuticals
Xiaflex
Roche
Novartis AG
Preventive Asthma Drug Segment by Type
Somatostatin Analogs
Chemotherapy
Targeted Therapy
Preventive Asthma Drug Segment by Application
Oncology Centres
Clinics
Hospital
Preventive Asthma Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preventive Asthma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Preventive Asthma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preventive Asthma Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Preventive Asthma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Preventive Asthma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Preventive Asthma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Somatostatin Analogs
- Chemotherapy
- Targeted Therapy
Applications
- Oncology Centres
- Clinics
- Hospital
Companies covered
- Callisto Pharmaceuticals
- Molecular Insight Pharmaceuticals
- Xiaflex
- Roche
- Novartis AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Preventive Asthma Drug Market Size (2021-2032)
- 2.2.2 Global Preventive Asthma Drug Sales (2021-2032)
- 2.2.3 Global Preventive Asthma Drug Market Average Price (2021-2032)
- 2.3 Preventive Asthma Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Somatostatin Analogs
- 2.3.3 Chemotherapy
- 2.3.4 Targeted Therapy
- 2.4 Preventive Asthma Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Oncology Centres
- 2.4.3 Clinics
- 2.4.4 Hospital
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Preventive Asthma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Preventive Asthma Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Preventive Asthma Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Preventive Asthma Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Preventive Asthma Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Preventive Asthma Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Preventive Asthma Drug, Product Type & Application
- 3.8 Global Manufacturers of Preventive Asthma Drug, Established Date
- 3.9 Global Preventive Asthma Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Callisto Pharmaceuticals
- 4.1.1 Callisto Pharmaceuticals Company Information
- 4.1.2 Callisto Pharmaceuticals Business Overview
- 4.1.3 Callisto Pharmaceuticals Preventive Asthma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Callisto Pharmaceuticals Preventive Asthma Drug Product Portfolio
- 4.1.5 Callisto Pharmaceuticals Recent Developments
- 4.2 Molecular Insight Pharmaceuticals
- 4.2.1 Molecular Insight Pharmaceuticals Company Information
- 4.2.2 Molecular Insight Pharmaceuticals Business Overview
- 4.2.3 Molecular Insight Pharmaceuticals Preventive Asthma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Molecular Insight Pharmaceuticals Preventive Asthma Drug Product Portfolio
- 4.2.5 Molecular Insight Pharmaceuticals Recent Developments
- 4.3 Xiaflex
- 4.3.1 Xiaflex Company Information
- 4.3.2 Xiaflex Business Overview
- 4.3.3 Xiaflex Preventive Asthma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Xiaflex Preventive Asthma Drug Product Portfolio
- 4.3.5 Xiaflex Recent Developments
- 4.4 Roche
- 4.4.1 Roche Company Information
- 4.4.2 Roche Business Overview
- 4.4.3 Roche Preventive Asthma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Roche Preventive Asthma Drug Product Portfolio
- 4.4.5 Roche Recent Developments
- 4.5 Novartis AG
- 4.5.1 Novartis AG Company Information
- 4.5.2 Novartis AG Business Overview
- 4.5.3 Novartis AG Preventive Asthma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis AG Preventive Asthma Drug Product Portfolio
- 4.5.5 Novartis AG Recent Developments
5 Global Preventive Asthma Drug Market Scenario by Region
- 5.1 Global Preventive Asthma Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Preventive Asthma Drug Sales by Region: 2021-2032
- 5.2.1 Global Preventive Asthma Drug Sales by Region: 2021-2026
- 5.2.2 Global Preventive Asthma Drug Sales by Region: 2027-2032
- 5.3 Global Preventive Asthma Drug Revenue by Region: 2021-2032
- 5.3.1 Global Preventive Asthma Drug Revenue by Region: 2021-2026
- 5.3.2 Global Preventive Asthma Drug Revenue by Region: 2027-2032
- 5.4 North America Preventive Asthma Drug Market Facts & Figures by Country
- 5.4.1 North America Preventive Asthma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Preventive Asthma Drug Sales by Country (2021-2032)
- 5.4.3 North America Preventive Asthma Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Preventive Asthma Drug Market Facts & Figures by Country
- 5.5.1 Europe Preventive Asthma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Preventive Asthma Drug Sales by Country (2021-2032)
- 5.5.3 Europe Preventive Asthma Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Preventive Asthma Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Preventive Asthma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Preventive Asthma Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Preventive Asthma Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Preventive Asthma Drug Market Facts & Figures by Country
- 5.7.1 South America Preventive Asthma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Preventive Asthma Drug Sales by Country (2021-2032)
- 5.7.3 South America Preventive Asthma Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Preventive Asthma Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Preventive Asthma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Preventive Asthma Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Preventive Asthma Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Preventive Asthma Drug Sales by Type (2021-2032)
- 6.1.1 Global Preventive Asthma Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Preventive Asthma Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Preventive Asthma Drug Revenue by Type (2021-2032)
- 6.2.1 Global Preventive Asthma Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Preventive Asthma Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Preventive Asthma Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Preventive Asthma Drug Sales by Application (2021-2032)
- 7.1.1 Global Preventive Asthma Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Preventive Asthma Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Preventive Asthma Drug Revenue by Application (2021-2032)
- 7.2.1 Global Preventive Asthma Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Preventive Asthma Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Preventive Asthma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Preventive Asthma Drug Value Chain Analysis
- 8.1.1 Preventive Asthma Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Preventive Asthma Drug Production Mode & Process
- 8.2 Preventive Asthma Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Preventive Asthma Drug Distributors
- 8.2.3 Preventive Asthma Drug Customers
9 Global Preventive Asthma Drug Analyzing Market Dynamics
- 9.1 Preventive Asthma Drug Industry Trends
- 9.2 Preventive Asthma Drug Industry Drivers
- 9.3 Preventive Asthma Drug Industry Opportunities and Challenges
- 9.4 Preventive Asthma Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst